Literature DB >> 24053199

Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts.

Alexey V Danilov1, Ryan S Soderquist, Darcy J P Bates, Alan Eastman.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24053199      PMCID： PMC3910377          DOI： 10.1586/14737140.2013.825424

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  22 in total

Review 1.  Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia.

Authors:  C Billard
Journal:  Leukemia       Date:  2012-03-28       Impact factor: 11.528

Review 2.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

3.  MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Authors:  M Konopleva; M Milella; P Ruvolo; J C Watts; M R Ricciardi; B Korchin; T McQueen; W Bornmann; T Tsao; P Bergamo; D H Mak; W Chen; J McCubrey; A Tafuri; M Andreeff
Journal:  Leukemia       Date:  2011-11-08       Impact factor: 11.528

4.  An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.

Authors:  Sayer Al-Harbi; Brian T Hill; Suparna Mazumder; Kamini Singh; Jennifer Devecchio; Gaurav Choudhary; Lisa A Rybicki; Matt Kalaycio; Jaroslaw P Maciejewski; Janet A Houghton; Alexandru Almasan
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

5.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

Authors:  Andrew W Roberts; John F Seymour; Jennifer R Brown; William G Wierda; Thomas J Kipps; Seong Lin Khaw; Dennis A Carney; Simon Z He; David C S Huang; Hao Xiong; Yue Cui; Todd A Busman; Evelyn M McKeegan; Andrew P Krivoshik; Sari H Enschede; Rod Humerickhouse
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

6.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

7.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

Authors:  Julia Hoellenriegel; Sarah A Meadows; Mariela Sivina; William G Wierda; Hagop Kantarjian; Michael J Keating; Neill Giese; Susan O'Brien; Albert Yu; Langdon L Miller; Brian J Lannutti; Jan A Burger
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

8.  Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data.

Authors:  C S Zent; M J Kyasa; R Evans; S A Schichman
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

9.  Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.

Authors:  Darcy J P Bates; Alexey V Danilov; Christopher H Lowrey; Alan Eastman
Journal:  Mol Cancer Ther       Date:  2013-05-30       Impact factor: 6.261

10.  Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo.

Authors:  R Soderquist; D J P Bates; A V Danilov; A Eastman
Journal:  Leukemia       Date:  2013-05-03       Impact factor: 11.528
View more
  4 in total

1.  Pro-apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B-cell receptor signalling in chronic lymphocytic leukaemia.

Authors:  Leigh A Humphries; J Claire Godbersen; Olga V Danilova; Prabhjot Kaur; Brock C Christensen; Alexey V Danilov
Journal:  Br J Haematol       Date:  2013-09-30       Impact factor: 6.998

2.  Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.

Authors:  C Paiva; J C Godbersen; A Berger; J R Brown; A V Danilov
Journal:  Cell Death Dis       Date:  2015-07-09       Impact factor: 8.469

3.  SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.

Authors:  Cody Paiva; Taylor A Rowland; Bhargava Sreekantham; Claire Godbersen; Scott R Best; Prabhjot Kaur; Marc M Loriaux; Stephen E F Spurgeon; Olga V Danilova; Alexey V Danilov
Journal:  Haematologica       Date:  2017-08-24       Impact factor: 9.941

4.  Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells.

Authors:  Cody Paiva; J Claire Godbersen; Ryan S Soderquist; Taylor Rowland; Sumner Kilmarx; Stephen E Spurgeon; Jennifer R Brown; Sreesha P Srinivasa; Alexey V Danilov
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.